Home » Stocks » ALXN

Alexion Pharmaceuticals, Inc. (ALXN)

Stock Price: $150.06 USD -0.04 (-0.03%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $150.68 +0.62 (0.41%) Mar 8, 7:56 PM
Market Cap 33.10B
Revenue (ttm) 6.07B
Net Income (ttm) 603.40M
Shares Out 220.10M
EPS (ttm) 2.72
PE Ratio 55.17
Forward PE 12.02
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $150.06
Previous Close $150.10
Change ($) -0.04
Change (%) -0.03%
Day's Open 149.21
Day's Range 149.17 - 151.11
Day's Volume 3,197,547
52-Week Range 72.67 - 162.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 days ago

Alexion (ALXN) reported earnings 30 days ago. What's next for the stock?

Business Wire - 4 days ago

BOSTON--(BUSINESS WIRE)--Alexion announces upcoming data presentations at the 73rd annual meeting of the American Academy of Neurology.

PRNewsWire - 1 week ago

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your...

Other stocks mentioned: BRPA, STPK
Zacks Investment Research - 1 week ago

The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.

Other stocks mentioned: ATVI, CSCO, MDLZ, MRNA, TMUS
Business Wire - 2 weeks ago

SAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

GuruFocus - 2 weeks ago

Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Ba...

Other stocks mentioned: GOLD, HZNP, RP, THRY
Zacks Investment Research - 3 weeks ago

Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Sanmina Corporation (SANM), Canadian Solar (CSIQ), Celestica (CLS) and Alexion Pharmaceuti...

Other stocks mentioned: CLS, CSIQ, SANM
Zacks Investment Research - 3 weeks ago

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Other stocks mentioned: BMRN
Zacks Investment Research - 3 weeks ago

Here are five of the 61 value stocks with discounted PEG.

Other stocks mentioned: ACI, AGCO, PPC, PVH
Zacks Investment Research - 3 weeks ago

Top Ranked Growth Stocks to Buy for February 10th

Other stocks mentioned: ACM, FLEX, MXL
Zacks Investment Research - 1 month ago

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.

Other stocks mentioned: AMGN, BBH, BIIB, GILD, IBB, XBI
Zacks Investment Research - 1 month ago

Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.

Zacks Investment Research - 1 month ago

Alexion (ALXN) delivered earnings and revenue surprises of 18.40% and 5.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Alexion Reports Fourth Quarter and Full Year 2020 Results

Zacks Investment Research - 1 month ago

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 1 month ago

These top-ranked stocks are likely to beat on bottom line in their next releases.

Other stocks mentioned: AVTR, DHI, QRVO, TTWO
Zacks Investment Research - 1 month ago

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.

Zacks Investment Research - 1 month ago

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.

Other stocks mentioned: ADNT, AMG, CSIQ, MTH
24/7 Wall Street - 1 month ago

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

Other stocks mentioned: AMGN, BIIB, GILD, MRK, PFE, ABBV, BMY, REGN
The Motley Fool - 1 month ago

You can still find deeply discounted stocks if you do a little digging.

Other stocks mentioned: CVS, T, VRTX, VZ, WBA
Zacks Investment Research - 1 month ago

Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Canadian Solar (CSIQ), Alexion Pharmaceuticals (ALXN), Vale S.A.

Other stocks mentioned: AMG, CSIQ, VALE
Zacks Investment Research - 1 month ago

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 month ago

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Other stocks mentioned: BMRN
Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31,...

Zacks Investment Research - 1 month ago

Here are five picks out of 45 top-ranked stocks with discounted PEG.

Other stocks mentioned: HUN, MRK, SBH, TGNA
Zacks Investment Research - 1 month ago

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

PRNewsWire - 1 month ago

NEW YORK, Jan. 14, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)...

Zacks Investment Research - 1 month ago

Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.

Zacks Investment Research - 1 month ago

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.

Other stocks mentioned: ADNT, AMG, GM
Market Watch - 1 month ago

Alexion Pharmaceuticals Inc. ALXN said late Wednesday it stopped enrolling patients in a clinical study testing a treatment for severe COVID-19 patients based on the recommendation of a data m...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference

Zacks Investment Research - 2 months ago

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Other stocks mentioned: BMRN
Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)--Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference

PRNewsWire - 2 months ago

NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) ...

PRNewsWire - 2 months ago

NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)...

The Motley Fool - 2 months ago

Dig a little deeper into the valuation.

Other stocks mentioned: AZN
The Motley Fool - 2 months ago

Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.

Other stocks mentioned: CRSP, VRTX
The Motley Fool - 2 months ago

These stocks have been struggling of late. Now could be a great time to scoop them up.

Other stocks mentioned: AZN, GOLD
PRNewsWire - 2 months ago

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

PRNewsWire - 2 months ago

NEW YORK, Dec. 16, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)...

The Motley Fool - 2 months ago

Here's why AstraZeneca's shareholders can expect healthy returns from this $39 billion investment.

Other stocks mentioned: AZN
GlobeNewsWire - 2 months ago

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Al...

Seeking Alpha - 2 months ago

Seeking Alpha Transcripts | Healthcare AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript) Dec. 15, 2020 9:50 AM ET | | About: AstraZeneca PLC (AZN), AZNCF by: SA...

Other stocks mentioned: AZN
GlobeNewsWire - 2 months ago

WILMINGTON, Del., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ GS: ALXN) regarding possible bre...

PRNewsWire - 2 months ago

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc....

The Motley Fool - 2 months ago

The Nasdaq Composite looked to get back into record territory on Monday.

Other stocks mentioned: PYPL
Zacks Investment Research - 2 months ago

Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.

Other stocks mentioned: AZN
Seeking Alpha - 2 months ago

Over the weekend, AstraZeneca made a $39 billion offer to acquire Alexion Pharmaceuticals in a deal that looks like it will benefit both parties.

Other stocks mentioned: AZN
The Motley Fool - 2 months ago

Alexion finally gets taken out.

Other stocks mentioned: AZN
24/7 Wall Street - 2 months ago

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca PLC (NASDAQ: AZN).

Other stocks mentioned: AZN

About ALXN

Alexion Pharmaceuticals develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patien... [Read more...]

Industry
Biotechnology
IPO Date
Feb 28, 1996
CEO
Ludwig Hantson
Employees
3,837
Stock Exchange
NASDAQ
Ticker Symbol
ALXN
Full Company Profile

Financial Performance

In 2020, ALXN's revenue was $6.07 billion, an increase of 21.61% compared to the previous year's $4.99 billion. Earnings were $603.40 million, a decrease of -74.90%.

Financial Statements

Analyst Forecasts

According to 18 analysts, the average rating for ALXN stock is "Hold." The 12-month stock price forecast is 172.65, which is an increase of 15.05% from the latest price.

Price Target
$172.65
(15.05% upside)
Analyst Consensus: Hold